Table 4.
Comparison of the CAPD and APD cost-effectiveness and incremental cost-utility ratio
| Item (Disease: Diabetic nephropathy, Age: 60–70 years) | APD (Mean±Standard deviation) | CAPD (Mean±Standard deviation) | Significant difference (p-value) | |
|---|---|---|---|---|
| Number of cases | (cases) | 9 | 9 | — |
| Age | (years) | 70.1±3.5 | 70.6±4.2 | n. s. |
| Males | (%) | 66.7 | 55.6 | n. s. |
| Dialysis duration | (months) | 18.6±31.7 | 18.5±16.5 | n. s. |
| Test values | ||||
| Residual Kt/V | 0.9±0.5 | 0.8±0.2 | n. s. | |
| BUN (mg/dL) | 44.0±12.7 | 49.7±13.3 | n. s. | |
| Alb (g/dL) | 3.4±0.2 | 3.0±0.6 | n. s. | |
| P (mg/dL) | 4.9±0.9 | 4.7±1.2 | n. s. | |
| K (mEq/L) | 4.3±0.4 | 4.2±0.5 | n. s. | |
| HDL (mg/dL) | 50.6±9.3 | 69.1±37.2 | n. s. | |
| TG (mg/dL) | 96.4±62.9 | 165.6±124.0 | * | |
| Utility (EQ−5D score, monthly conversion) |
0.987±0.039 | 0.860±0.164 | * | |
| Medical costs (medical department outpatient, US$/month) |
4,591±1,494 | 3,275±1,204 | ** | |
| Cost-utility analysis (US$/QALY, annual conversion) |
59,830±19,376 | 49,023±66,773 | * | |
| Incremental cost-utility ratio | ||||
| (ICUR: CAPD vs. APD calculation) | 126,034 (12–24 months after intervention: 74,598) | |||
| (US$/QALY, annual conversion) | ||||
Notes: Welch’s t-test *p < 0.05, **p < 0.01, n. s.: not significant.